Jump to content

Drilldown: Medicines

Choose a table:


Medicines > preparations : 0.025%, 0.035% ophthalmic solutions or None

Use the filters below to narrow your results.

generic:
 
brand:
None (237)
classes:
Research material (131) · Classic Psychedelic (70) · Stimulant (43) · Opioid (31) · Sedative-Hypnotic (29) · Phenethylamine (26) · Tryptamine (26) · Botanical (23) · Benzodiazepine (22) · Anticonvulsant (19) · Dissociative (19) · Antidepressant (18) · Analgesic (17) · Antipsychotic (17) · Antiparkinsonian (16) · Empathogen (16) · Neuroleptic (16) · Cathinone (14) · Lysergamide (13) · Nootropic (13)
mechanism:
5-HT2A agonist (27) · GABAA positive allosteric modulator (22) · None (11) · Monoamine releasing agent (11) · CB1/CB2 agonist (7) · Potent mu-opioid receptor agonist (6) · Sodium channel blocker (6) · Dopamine/norepinephrine reuptake inhibitor (5) · GABAA potentiator; NMDA antagonist (5) · Phenothiazine D2 antagonist (5) · Potent 5-HT2A agonist (5) · 5-HT1B/1D agonist (4) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Muscarinic receptor antagonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Selective norepinephrine reuptake inhibitor (4)
 
uses:
None (398) · ADHD, narcolepsy (1) · Antimanic, Antidepressive, Antisuicide (1) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Pain, cough, disquiet (1) · Schizophrenia, acute psychosis, agitation, delirium, Tourette syndrome, severe nausea (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) · '"`UNIQ--vote-00001286-QINU`"' (1)
starting dose:
None (404) · Ophthalmic 1 drop in each eye every 8-12 hours (1)
preparations: (Click arrow to add another value)
fda max:
None (404) · 1 drop per eye q8-12h (1)
routes:
None (398) · IM (1) · insufflated (1) · IV (1) · Oral (6) · PR (1) · Topical ophthalmic (1) · transdermal (1)
onset:
None (398) · 20–60 min (oral) (1) · 30–60 min (1) · 30–60 minutes (1) · 45-75 min (oral) (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · PO 1–2 h; IM 30–60 min; IV 5–20 min (1) · Within minutes (1)
duration:
None (397) · 12–24 h (oral); decanoate IM 3–4 weeks (1) · 4-8 h (1) · 8-12 hours (1) · 8–12 hours (1) · About 20 minutes (1) · Chronic daily dosing (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 8–12 h (1)
halflife:
None (397) · 14–26 h (oral); ~3 weeks (decanoate) (1) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1) · 3–5 hours (1) · 9–12 minutes (intravenous) (1) · Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) · Not well characterized (1) · ~12 hours (1)
bioavailability:
None (398) · 70–90% (oral) (1) · Not well characterized (1) · Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1) · ~22–25% (1) · ~30% (high first-pass) (1) · ~50% (highly variable) (1) · ~60–70% (oral) (1)
pregnancy:
None (398) · Category C (3) · Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (2) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)
legal:
None (397) · OTC in US (1) · Rx-only (2) · Schedule I (United States) (1) · Schedule II (2) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (2)

Showing below up to 250 results in range #1 to #250.

View (previous 250 | ) (20 | 50 | 100 | 250 | 500)

1

2

3

4

5

6

7

A

B

C

D

E

F

G

H

I

J

K

L


View (previous 250 | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"